These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11057343)

  • 41. Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.
    Corum I; Yeniad B; Bilgin LK; Ilhan R
    J Ocul Pharmacol Ther; 2005 Oct; 21(5):400-5. PubMed ID: 16245967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
    Rosenwasser LJ; O'Brien T; Weyne J
    Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of the effects of olopatadine and ketotifen on model membranes.
    Brockman H; Graff G; Spellman J; Yanni J
    Acta Ophthalmol Scand Suppl; 2000; (230):10-5. PubMed ID: 11057342
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism.
    Matsumoto Y; Funahashi J; Mori K; Hayashi K; Yano H
    Pharmacology; 2008; 81(3):266-74. PubMed ID: 18268402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis.
    Sharif NA; Xu SX; Yanni JM
    J Ocul Pharmacol Ther; 1996; 12(4):401-7. PubMed ID: 8951676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
    Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
    Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
    Ohmori K; Hasegawa K; Tamura T; Miyake K; Matsubara M; Masaki S; Karasawa A; Urayama N; Horikoshi K; Kajita J; Hasegawa M; Taniguchi K; Komada T; Kawamoto Y
    Arzneimittelforschung; 2004; 54(12):809-29. PubMed ID: 15646365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ; Stoppel JO; Epstein AB
    Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.
    Tamura T; Matsubara M; Hasegawa K; Ohmori K; Karasawa A
    Clin Exp Allergy; 2005 Jan; 35(1):97-103. PubMed ID: 15649273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.
    Lekhanont K; Park CY; Combs JC; Suwan-Apichon O; Rangsin R; Chuck RS
    J Ocul Pharmacol Ther; 2007 Feb; 23(1):83-8. PubMed ID: 17341156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
    Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Turner FD; Wells DT; Robertson SM
    Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
    Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
    Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
    Villareal AL; Farley W; Pflugfelder SC
    Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model.
    Novack GD
    Clin Ther; 2002 Sep; 24(9):1477-8; author reply 1478-80. PubMed ID: 12380639
    [No Abstract]   [Full Text] [Related]  

  • 56. The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice.
    Tamura T; Amano T; Ohmori K; Manabe H
    Eur J Pharmacol; 2005 Nov; 524(1-3):149-54. PubMed ID: 16259975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advantages of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis.
    Matsushita A; Seike M; Okawa H; Kadawaki Y; Ohtsu H
    Exp Dermatol; 2012 Sep; 21(9):714-5. PubMed ID: 22897580
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
    McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
    Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein.
    Kishimoto K; Kaneko S; Ohmori K; Tamura T; Hasegawa K
    Mediators Inflamm; 2006; 2006(1):42726. PubMed ID: 16864903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.